TALAPRO-3 — Talazoparib plus Enzalutamide in DDR/HRR Gene-Altered Metastatic Castration-Sensitive Prostate Cancer

Phase 3 · 2025 · Prostate Cancer

Design

Randomized, double-blind, placebo-controlled trial of talazoparib plus enzalutamide versus placebo plus enzalutamide, with androgen deprivation therapy.

Population

Men with DNA damage response (DDR) / homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC).

Primary Endpoint

radiographic progression-free survival (rPFS)

Key Result

Talazoparib plus enzalutamide produced a statistically significant and clinically meaningful improvement in radiographic progression-free survival versus enzalutamide alone in DDR/HRR-altered mCSPC.

Guideline Impact

First-line DDR/HRR-altered metastatic castration-sensitive prostate cancer